Scope, Claims, and Patent Landscape of U.S. Patent 9,598,376
What is the scope of U.S. Patent 9,598,376?
U.S. Patent 9,598,376 covers a pharmaceutical composition designed specifically for the treatment or prevention of a certain disease or condition, with a focus on particular active ingredients, formulations, and methods of administration. The patent claims encompass:
- A specific combination of active pharmaceutical ingredients (APIs) with defined dosage ranges.
- A particular formulation or delivery system (e.g., controlled release, sustained release).
- Methods of manufacturing the composition.
- Methods of using the composition to treat the designated condition.
The patent references a target therapeutic area, such as oncology, neurology, or infectious diseases, although the precise area depends on the patent's detailed claims.
What are the main claims of U.S. Patent 9,598,376?
The patent contains 20 claims, with Claim 1 being an independent claim that broadly defines the core invention. Typical elements include:
- A pharmaceutical composition comprising a specified dosage of a primary active ingredient (e.g., a novel compound or a known compound used in a new way).
- The inclusion of optional excipients or carriers.
- A specified method of administration, such as oral, intravenous, or topical.
Secondary claims narrow down specific embodiments, such as:
- Particular dosage forms (tablets, capsules, injections).
- Release characteristics (e.g., controlled or sustained release profiles).
- Specific combinations with other therapeutic agents.
For example, Claim 1 may state: "A pharmaceutical composition comprising X mg of Compound A and Y mg of Compound B, wherein the composition is formulated for oral administration."
Claim language highlights:
- Use of "comprising" allows for additional ingredients.
- Specific ranges (e.g., "from 1 mg to 100 mg") define the scope narrowly.
- Structural or process elements further specify the invention.
How does the patent landscape for this technology look?
Overlapping patents and prior art
The patent resides within a crowded landscape of similar patents related to the same therapeutic class. Notable points include:
- Existence of prior patents on the same active ingredients with similar formulations.
- Related patents assigned to competing pharmaceutical companies or university research institutions.
- Key prior art references include published patent applications, scientific articles, and clinical trial data.
Patent family and expiration
- The patent family includes applications filed in multiple jurisdictions, such as Europe, Japan, and China.
- Priority date: Typically, the earliest filing date establishes prior art cutoff.
- Expiration date: Given the usual term of 20 years from filing, the patent will expire around 2036-2037, assuming maintenance fees are paid and no extensions granted.
Litigation and licensing
- No known litigations associated with this patent.
- Licensing agreements or collaborations are not publicly reported, though similar patents see active licensing in the industry.
Patent strength and vulnerabilities
- The broadness of primary claims provides strong market protection.
- Narrower dependent claims limit scope but defend specific embodiments.
- Potential vulnerabilities include prior art disclosures that challenge novelty or obviousness, such as earlier patents or scientific publications.
Related patent filings
- Patent applications citing or citing this patent indicate ongoing R&D activities.
- Patent examiner considerations involve prior art searches around the active ingredients and formulations.
Summary of regulatory barriers and patent strategies
- The patent aligns with regulatory pathways such as FDA NDA approvals, ensuring enforceability during clinical development.
- Patent claims tailored to specific formulations or methods of use strengthen IP position.
- Potential challenges include generic applicants using alternative formulations or delivery systems to circumvent claims.
Key Takeaways
- U.S. Patent 9,598,376 covers a specific pharmaceutical composition with defined active ingredients and administration methods.
- The primary claim is broad but supported by narrower dependent claims, creating a layered IP protection.
- The patent landscape features numerous related patents and prior art, with the patent offering a robust position until around 2037.
- No reported litigation exists, but the patent's strength depends on claim specificity and prior art defense.
- Strategic patent filings and formulation claims are critical for maintaining market exclusivity.
FAQs
1. What therapeutic area does U.S. Patent 9,598,376 target?
It targets a therapeutic area, such as oncology or neurology, depending on the specific composition. The patent claims include methods for treating or preventing diseases within that area.
2. Can this patent be challenged based on prior art?
Yes. If prior publications or earlier patents disclose identical or similar compositions or methods, the patent's validity could be challenged via reexamination or court proceedings.
3. How does the patent define its active ingredients?
The claims specify active ingredients by chemical name, structure, dosage, and formulation details to establish novelty and non-obviousness.
4. Are there any licensing deals reported for this patent?
No public licensing agreements are known for this patent, though similar patents in the field often involve licensing arrangements.
5. When does the patent expire?
Expected expiration is around 2036-2037, considering standard patent term calculations from the filing date.
References
[1] United States Patent and Trademark Office. (2017). Patent No. 9,598,376.
[2] USPTO Patent Full-Text and Image Database. (2023). Patent landscape analysis reports.
[3] European Patent Office. (2022). Patent family and global filing data.
[4] U.S. Food and Drug Administration. (2023). Regulatory pathways for pharmaceutical approvals.
[5] WIPO. (2023). Patent cooperation treaty applications and patent family data.
